Dr. Daniel Goldstein reviews data from ASCO 2018 on patient-reported quality of life on atezolizumab/bevacizumab compared to sunitinib in metastatic kidney cancer, along with the context of other treatment options in this setting.
Quality of Life on the Atezolizumab/Bevacizumab Combination for Metastatic Kidney Cancer: Highlights from ASCO 2018 (BMIC-054)
